

CERUS CORP  
Form 8-K  
June 05, 2003

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 4, 2003

## CERUS CORPORATION

(Exact name of registrant as specified in its charter)

**Delaware**  
(State of jurisdiction)

**0-21937**  
(Commission File No.)

**68-0262011**  
(IRS Employer Identification  
No.)

**2411 Stanwell Drive**  
**Concord, California 94520**  
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(925) 288-6000**

**Item 5. Other Events.**

On June 4, 2003, Cerus Corporation (the Company) and Baxter International, Inc. (Baxter) announced that the Company and Baxter reached agreement with the U.S. Food and Drug Administration on steps for regulatory approval for their pathogen inactivation system for platelets. A copy of the Company's press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

**Item 7. Exhibits.**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release, dated June 4, 2003, entitled Baxter and Cerus Reach Agreement With FDA On Steps To Gain Regulatory Approval For Innovative Pathogen Inactivation System.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CERUS CORPORATION**

Dated: June 4, 2003

By: */s/ Gregory W. Schafer*  
Gregory W. Schafer  
Vice President, Finance and  
Chief Financial Officer

**Index to Exhibits**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release, dated June 4, 2003, entitled Baxter and Cerus Reach Agreement With FDA On Steps To Gain Regulatory Approval For Innovative Pathogen Inactivation System.